Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Phase 2 Completed
363 enrolled 16 charts
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
Phase 1 Terminated
3 enrolled 9 charts
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
Phase 2 Completed
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase 2 Completed
57 enrolled 10 charts
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
Phase 3 Completed
225 enrolled 12 charts
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Completed
17 enrolled
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Withdrawn
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Phase 2 Completed
66 enrolled 7 charts
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Phase 3 Terminated
72 enrolled 15 charts
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
Phase 3 Unknown
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Unknown
Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase 3 Unknown
312 enrolled
Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer
Phase 1 Completed
30 enrolled
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase 3 Unknown
900 enrolled
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
Phase 3 Completed
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Phase 3 Unknown
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase 2 Unknown
20 enrolled
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase 2/3 Completed
3,240 enrolled
Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
Phase 3 Completed
2,500 enrolled
Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed
Phase 3 Completed
1,800 enrolled
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Phase 1 Completed
24 enrolled
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
Phase 1 Completed
54 enrolled
Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer
Phase 3 Unknown
774 enrolled
Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer
Phase 3 Unknown
1,050 enrolled
Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
Phase 3 Unknown
336 enrolled
Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Phase 2 Completed
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase 2 Completed
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
Phase 2 Completed
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 1/2 Completed
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Phase NA Completed
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
Phase 2 Completed
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Phase 2 Completed
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
Phase 2 Completed
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 2 Terminated
26 enrolled
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase 1 Completed
22 enrolled
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
Phase 2 Completed
40 enrolled
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Phase 3 Terminated
2,200 enrolled
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
Phase 3 Completed
880 enrolled
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Phase 2 Terminated
50 enrolled
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
Phase 1 Completed
20 enrolled
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase 3 Completed
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
Phase 2 Unknown
100 enrolled
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
Phase 2 Completed
45 enrolled
Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase 2 Completed
80 enrolled
Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer
Phase 2 Unknown
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
Phase 3 Unknown
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Phase 2/3 Unknown
600 enrolled
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
Phase 2 Unknown
35 enrolled
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Phase 2 Unknown
206 enrolled
Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Unknown